A practical reference on REV-ERB agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-25. Anything still debated is marked as such rather than presented as settled.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
== Classification == IRP results when the upper rectum engages the lower rectum. The intussusception usually starts on the anterior (ventral, i.e. front) surface of the rectal wall. Later, the prolapsing segment expands circumferentially to include the posterior (back) wall of the rectum. The prolapse usually occurs at the level of the pouch of Douglas, 8–10 cm from the anal verge. IRP occurs when pressure in the abdominal cavity increases, especially during defecation. The lowest point of the intussusception is called the apex. The lowest point reached by the apex is used in classification systems to establish the grade (severity) of IRP. Intra-rectal (recto-rectal / high grade) prolapse is when the prolapsed segment remains within the rectum. Intra-anal (recto-anal / low grade) prolapse is when the prolapsed segment extends into the anal canal. Other important features are the thickness of the prolapsed segment, and the distance between the point of inversion as measured from the anal verge. The first attempt at classification of rectal prolapse appeared in 1971. This classification divided rectal prolapse into 3 types according to the layers of tissue involved and the relationship to cul-de-sac hernia and hemorrhoids. Type I was prolapse of redundant mucosal layer of the rectal wall by 1–3 cm. They stated that this type was common but also was a false prolapse. Type II was described as full-thickness intussusception of the rectum and recto-sigmoid (the last part of the sigmoid) through the anal canal and without any associated cul-de-sac sliding hernia.
== Inhibition of translation == Puromycin is an aminonucleoside antibiotic, derived from the Streptomyces alboniger bacterium, that causes premature chain termination during translation taking place in the ribosome. Part of the molecule resembles the 3' end of the aminoacylated tRNA. It enters the A site and transfers to the growing chain, causing the formation of a puromycylated nascent chain and premature chain release. The exact mechanism of action is unknown at this time but the 3' position contains an amide linkage instead of the normal ester linkage of tRNA. That makes the molecule much more resistant to hydrolysis and stops the ribosome. Puromycin is selective for either prokaryotes or eukaryotes. Also of note, puromycin is critical in mRNA display. In this reaction, a puromycin molecule is chemically attached to the end of an mRNA template, which is then translated into protein. The puromycin can then form a covalent link to the growing peptide chain allowing the mRNA to be physically linked to its translational product. Antibodies that recognize puromycylated nascent chains can also be used to purify newly synthesized polypeptides and to visualize the distribution of actively translating ribosomes by immunofluorescence.
The idea of hexapods being 'terrestrial crustaceans' is relatively recent, coming from a 2005 molecular analysis study. A 2013 study restructured the relationships within Pancrustacea, and first proposed the name Allotriocarida. The most recent study of Allotriocarida in 2019 provides additional evidence suggesting that Hexapoda and Remipedia are likely more closely related to each other than to Cephalocarida or Branchiopoda. As of 2024, the existence of Allotriocarida as a monophyletic group within Pancrustacea is now much more widely accepted than the Atelocerata classification which dates back to the 19th century. This formerly-held belief was that hexapods and myriapods (centipedes, millipedes, etc.) are more closely related to each other than they are to the Multicrustacea, based on morphological similarities in their tracheae, but this proposition has been contradicted by the aforementioned modern molecular phylogenetic studies. The most recent understanding of Allotriocarida, as described in the 2019 study, can be seen in the cladogram below.
Sources: en.wikipedia.org
Simon Khung, a social media influencer who eventually stopped taking drugs after the 2020 murder of his daughter Megan Khung (who was allegedly killed by her mother), told a newspaper in 2024 that he supported the death penalty for drug trafficking, as he felt that the drug situation in Singapore would grow worse in the absence of capital punishment and more people would become drug abusers and ruin their lives like he and the former abusers had in their pasts; Khung's stance was supported by other ex-abusers, and one of them, Bruce Mathieu (who overcame his drug addiction seven years prior), said that the death penalty had deterred him from resorting to drug smuggling. In the aftermath of several executions, there were discussions among the Singaporean public about the need for compassion for some death row inmates, owing to arguments that many death row inmates had come from low-income families or had drug addictions before ending up on death row. However, the public sentiments remained leaning towards capital punishment for drugs, owing to arguments concerning rampant rates of drug trafficking in the Golden Triangle in Southeast Asia, the effectiveness of the death penalty in maintaining Singapore's low crime rate, and the impact drugs have had on the addicts and their families. When 31-year-old Singaporean Shen Hanjie was sentenced to death for trafficking 34.94g of pure heroin in October 2022, a huge majority of the netizens showed support for the death sentence in Shen's case, with some expressing sympathy for his family, especially his parents.
== Satisfaction and burnout == A survey of physicians in the United States came to the result that dermatologists are most satisfied with their choice of specialty followed by radiologists, oncologists, plastic surgeons, and gastroenterologists. In contrast, primary care physicians were the least satisfied, followed by nephrologists, obstetricians/gynecologists, and pulmonologists. Surveys have also revealed high levels of depression among medical students (25 - 30%) as well as among physicians in training (22 - 43%), which for many specialties, continue into regular practice. A UK survey conducted of cancer-related specialties in 1994 and 2002 found higher job satisfaction in the specialties with more patient contact. Rates of burnout also varied by specialty.
=== Deep Learning === More recently, deep learning techniques have been applied to solve the de novo peptide sequencing problem. The first breakthrough was DeepNovo, which adopted the convolutional neural network structure, achieved major improvements in sequence accuracy, and enabled complete protein sequence assembly without assisting databases Subsequently, additional network structures, such as PointNet (PointNovo), have been adopted to extract features from a raw spectrum. The de novo peptide sequencing problem is then framed as a sequence prediction problem. Given previously predicted partial peptide sequence, neural-network-based de novo peptide sequencing models will repeatedly generate the most probable next amino acid until the predicted peptide's mass matches the precursor mass. At inference time, search strategies such as beam search can be adopted to explore a larger search space while keeping the computational cost low. Comparing with previous methods, neural-network-based models have demonstrated significantly better accuracy and sensitivity. Moreover, with a careful model design, deep-learning-based de novo peptide sequencing algorithms can also be fast enough to achieve real-time peptide de novo sequencing. PEAKS software incorporates this neural network learning in their de novo sequencing algorithms.
Sources: en.wikipedia.org
=== Pet food === In the US, Turkestan cockroaches are sometimes kept to feed to pet reptiles and other insectivores, chosen partly because they can't climb smooth surfaces and don't burrow. Cockroaches have been replacing crickets, the most popular feeder insect for decades, due to the cricket's noise, odor, short lifespan, and expense. Turkestan cockroaches are a popular choice of species, and are readily available for sale over the Internet, which may hasten their spread to new habitats. Although reliable information on specific dietary requirements of insectivores is scant, Turkestan cockroaches provide a high-protein, low fat nutrition composition similar to crickets, more so than mealworms or superworm larvae provide. The gut contents of the cockroach, depending on its diet, may provide essential nutrients unavailable from a cockroach with an empty gut. In a study of commercially ordered specimens, small second instar nymphs (0.9–1.3 cm or 0.35–0.51 in) consisted of 21% dry matter, made of 76% crude protein and 14% crude fat, while medium third instar nymphs (1.3-1.9 cm) consisted of 28% dry matter, made of 53% crude protein and 27% crude fat. Mineral content is well represented except for a low calcium:phosphorus ratio typical in cockroaches, and calcium supplementation may be advisable. Vitamin A and E content was relatively low, and is generally significantly higher in free-ranging cockroaches.
==== Cleaved, contracted, and expanded rings ==== Secosteroids (Latin seco, "to cut") are a subclass of steroidal compounds resulting, biosynthetically or conceptually, from scission (cleavage) of parent steroid rings (generally one of the four). Major secosteroid subclasses are defined by the steroid carbon atoms where this scission has taken place. For instance, the prototypical secosteroid cholecalciferol, vitamin D3 (shown), is in the 9,10-secosteroid subclass and derives from the cleavage of carbon atoms C-9 and C-10 of the steroid B-ring; 5,6-secosteroids and 13,14-steroids are similar. Norsteroids (nor-, L. norma; "normal" in chemistry, indicating carbon removal) and homosteroids (homo-, Greek homos; "same", indicating carbon addition) are structural subclasses of steroids formed from biosynthetic steps. The former involves enzymic ring expansion-contraction reactions, and the latter is accomplished (biomimetically) or (more frequently) through ring closures of acyclic precursors with more (or fewer) ring atoms than the parent steroid framework. Combinations of these ring alterations are known in nature. For instance, ewes who graze on corn lily ingest cyclopamine (shown) and veratramine, two of a sub-family of steroids where the C- and D-rings are contracted and expanded respectively via a biosynthetic migration of the original C-13 atom. Ingestion of these C-nor-D-homosteroids results in birth defects in lambs: cyclopia from cyclopamine and leg deformity from veratramine. A further C-nor-D-homosteroid (nakiterpiosin) is excreted by Okinawan cyanobacteriosponges.
Recent developments that exploit proximal functional groups have enabled hydrazone condensations to operate at 20 M−1s−1 at neutral pH while oxime condensations have been discovered which proceed at 500-10000 M−1s−1 at neutral pH without added catalysts.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.